# US 2025/0154458 A1 · Methods for Making, Compositions Comprising, and Methods of Using Rejuvenated T Cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154458 A1
- Document ID: US20250154458A1
- Status: Published application
- Kind: A1
- Application number: 18/807,470
- Filed: 2024-08-16
- Published: 2025-05-15
- Earliest claimed: 2020-11-24
- Assignees: Lyell Immunopharma, Inc.
- Applicants: Lyell Immunopharma, Inc.
- Inventors: Raul E. VIZCARDO SAKODA; Nicholas RESTIFO, I; Richard D. KLAUSNER; Yin HUANG; Takuya MAEDA; Naritaka TAMAOKI; Yasuhiro YAMAZAKI
- Web page: https://patentgrep.com/patent/US20250154458A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/4211: {CD19 or B4}
- A61K 40/4269: {NY-ESO}
- A61P 35/00: Antineoplastic agents
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2501/602: Sox-2
- C12N 2501/603: Oct-3/4
- C12N 2501/604: Klf-4
- C12N 2501/606: c-Myc
- C12N 2510/00: Genetically modified cells
- C12N 2760/18821: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/18842: virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- C12N 2760/18843: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates generally to methods of producing rejuvenated T cells, comprising, contacting T cells with at least one reprogramming factor and reactivating the contacted cells; and compositions and methods of using same. The present disclosure also describes cell populations prepared according to methods described herein. The disclosure also provides for methods of treating patients using cell populations prepared by the methods described herein.

## Claims

### Claim 1

A method of producing rejuvenated T cells, comprising
(a) contacting a population of T cells with (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3/4, SOX2 and C-MYC, and (ii) optionally SV40, for a period of time sufficient for a T cell derived adherent cell to form and wherein said T cells are not transformed into iPS or totipotent cell; and
(b) contacting the T cell derived adherent cell with at least one T cell activating compound.

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

The method of claim 1, wherein:
(a) the T cells are contacted with the at least one reprogramming factor for a period of time sufficient for at least a portion of the T cells to express CD3 and at least one marker selected from the group consisting of integrin α6β1, SSEA4, CD9, and CD90;
(b) the T cells are contacted with the at least one reprogramming factor for a period of time sufficient for at least a portion of said contacted T cells to express CD3, SSEA4, CD9 and CD90; or
(c) any combination of (a) and (b).

### Claim at position 4

6-8. (canceled)

### Claim 9 (depends on 1)

The method of claim 1, wherein, prior to contacting said T cells with the at least one reprogramming factor, the T cells are activated with IL-2 and at least one agent capable of activating said T cells.

### Claim 10 (depends on 1)

The method of claim 1, wherein the T cells are TCRαβ cells, TCRγδ cells; CD4+CD8αβ+ double positive cells, CD4+ single positive cells (such as Th1, Th2, Th17, Treg), naïve T cells, central memory T cells, effector memory T cells, or a combination thereof.

### Claim 11 (depends on 9)

The method of claim 9, wherein the activated T cells are enriched by selection for cells expressing CD137, PD1, or LAG3.

### Claim at position 8

12-13. (canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the T cells are contacted with KLF4, OCT3/4, SOX2 and C-MYC.

### Claim 15 (depends on 14)

The method of claim 14, wherein the T cells are contacted with KLF4, OCT3/4, SOX2 and C-MYC for at least about 4 to about 10 days.

### Claim at position 11

16-17. (canceled)

### Claim 18 (depends on 1)

The method of claim 1 wherein the at least one reprogramming factor is expressed in the T cell.

### Claim 19 (depends on 18)

The method of claim 18, wherein the at least one reprogramming factor is expressed using a non-integrating viral vector, optionally wherein the at least one reprogramming factor is expressed using a Sendai virus.

### Claim 20

(canceled)

### Claim 21 (depends on 18)

The method of claim 18, wherein the at least one reprogramming factor is expressed, wherein expression is later inhibited by the addition of a compound that inhibits expression of the at least one reprogramming factor.

### Claim 22

(canceled)

### Claim 23 (depends on 18)

The method of claim 18, wherein expression of the at least one reprogramming factor is inhibited by contacting the T cell derived adherent cells with an agent that activates T cells.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The method of claim 1, further comprising contacting the T cells with a cytokine.

### Claim 26 (depends on 1)

The method of claim 1, wherein said at least one T cell activating agent comprises an antibody that binds CD3 or an antibody that binds CD28 or both; or wherein the at least one T cell activating agent is a tumor antigen.

### Claim 27 (depends on 1)

The method of claim 1, further comprising engineering the T cells to express a chimeric antigen receptor (CAR), a T cell Receptor or hybrid receptor thereof, wherein said T cells are engineered prior to contacting said T cells with said at least one reprogramming factor, and wherein said surface receptor recognizes a specific antigen on the surface of a target cell.

### Claim 28 (depends on 1)

The method of claim 1, further comprising engineering the T cells to express a CAR, a T cell Receptor or a hybrid receptor thereof, wherein said T cells are engineered after contacting said T cells with said at least one reprogramming factors, and wherein said cell surface receptor recognizes a specific antigen on the surface of a target cell.

### Claim at position 23

29-32. (canceled)

### Claim 33 (depends on 1)

The method of claim 1, wherein;
(a) the resulting T cells comprise an incomplete set of V, D, and J segments of T cell receptor genes;
(b) the epigenetic age of the resulting T cells is at least 5% younger than the population of T cells prior to reprogramming;
(c) the partially reprogrammed T cells are capable of expanding at least 25-fold greater than control T cells;
(d) contacting said T cells with (i) at least one factor selected from the group consisting of KLF4, OCT3/4, SOX2 and C-MYC; and (ii) SV40 results in a reduction in CD3 and CD8 expression; or
(e) any combination of (a) to (d).

### Claim at position 25

34-50. (canceled)

### Claim 51

A population of T cells produced by a method comprising
a) contacting a population of T cells with (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3/4, SOX2 AND C-MYC, and (ii) optionally SV40, for a period of time sufficient for T cell derived adherent cells to form and wherein said T cells are not transformed into iPS or totipotent cells; and
b) contacting the T cell derived adherent cells with at least one T cell activating agent.

### Claim at position 27

52-90. (canceled)

### Claim 91 (depends on 1)

A method of treating a subject in need thereof with a population of T cells produced by the method of claim 1.

### Claim at position 29

92-97. (canceled)

### Claim 98

A method of producing a rejuvenated tumor infiltrating lymphocyte (TIL), comprising
a) activating a population of TIL with a first tumor antigen, such that the activated TILs express CD137; optionally, enriching the CD137+ TIL;
b) contacting the population of activated TILs with (i) at least one reprogramming factor selected from the group consisting of KLF4, OCT3/4, SOX2 and C-MYC, and (ii) optionally SV40, for a period of time sufficient for TIL-derived adherent cells to form; wherein said TILs are not transformed into iPS or totipotent cells.

### Claim at position 31

99-109. (canceled)

### Claim 110 (depends on 98)

A method of treating cancer in a patient in need thereof with a population of rejuvenated TILs produced by the method of claim 98.

### Claim at position 33

111-112. (canceled)
